These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29397867)

  • 1. Structure and function of vascular endothelial growth factor and its receptor system.
    Park SA; Jeong MS; Ha KT; Jang SB
    BMB Rep; 2018 Feb; 51(2):73-78. PubMed ID: 29397867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
    Shibuya M
    J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
    Shibuya M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF signal system: the application of antiangiogenesis.
    Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
    Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF as a key mediator of angiogenesis in cancer.
    Carmeliet P
    Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling.
    Hu WH; Duan R; Xia YT; Xiong QP; Wang HY; Chan GK; Liu SY; Dong TT; Qin QW; Tsim KW
    J Agric Food Chem; 2019 Jan; 67(4):1127-1137. PubMed ID: 30525561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
    Moreira IS; Fernandes PA; Ramos MJ
    Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
    Sharma PS; Sharma R; Tyagi T
    Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M
    BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches.
    Kuhn H; Hammerschmidt S; Wirtz H
    Curr Med Chem; 2007; 14(30):3157-65. PubMed ID: 18220749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy.
    Shaik F; Cuthbert GA; Homer-Vanniasinkam S; Muench SP; Ponnambalam S; Harrison MA
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33333800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
    Bender RJ; Mac Gabhann F
    BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.